[1]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638-640.[doi:10.13798/j.issn.1009-153X.2015.10.022]
点击复制

贝伐单抗治疗复发胶质母细胞瘤的研究进展()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2015年10期
页码:
638-640
栏目:
论著
出版日期:
2015-10-30

文章信息/Info

文章编号:
1009-153X(2015)10-0638-03
作者:
宋贵东 综述 高之宪 审校
100050 北京,首都医科大学附属北京天坛医院神经外科
关键词:
胶质母细胞瘤复发贝伐单抗研究进展
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2015.10.022
文献标志码:
B

参考文献/References:

[1] Franceschi E, Tosoni A, Bartolini S, et al. Treatment options for recurrent glioblastoma: pitfalls and future trends [J]. Expert Rev Anticancer Ther, 2009, 9(5): 613-619.
[2] Chamberlain M. Evolving strategies: future treatment of glioblastoma [J]. Expert Rev Neurother, 2014, 11(4): 519- 532.
[3] Pazdur R. Endpoints for assessing drug activity in clinical trials [J]. Oncologist, 2008, 13 Suppl 2: 19-21.
[4] Franceschi E, Agati R, Brandes AA. End points for Phase Ⅱ trials in recurrent glioblastoma: the cornerstone for a new era [J]. Expert Rev Anticancer Ther, 2011, 11(11): 1713- 1717.
[5] Johansson F, Ekman S, Blomquist E, et al. A review of dose- dense temozolomide alone and in combination with bevaci- zumab in patients with first relapse of glioblastoma [J]. Anticancer Res, 2012, 32(9): 4001-4006.
[6] Kreisl T N, Kim L, Moore K, et al. Phase Ⅱ trial of single- agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma [J]. J Clin Oncol, 2009, 27(5): 740-745.
[7] Vredenburgh JJ, Desjardins A, Herndon JN, et al. Bevaci- zumab plus irinotecan in recurrent glioblastoma multiforme [J]. Ann Oncol, 2013, 32(7): 2003-3006.
[8] Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival [J]. J Neuro- surg, 2009, 110(1): 173-180.
[9] Poulsen H S, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours [J]. Acta Oncol, 2009, 48(1): 52-58.
[10] Cao Y, Tan A, Gao F, et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer [J]. Int J Colorectal Dis, 2009, 24(6): 677-685.
[11] Verhoeff J J, Lavini C, van Linde M E, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma [J]. Ann Oncol, 2010, 21(8): 1723-1727.
[12] Gorski D H, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation [J]. Cancer Res, 2014, 59(14): 3374-3378.
[13] Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J]. Nature, 2006, 444(7120): 756- 760.
[14] Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas [J]. Int J Radiat Oncol Biol Phys, 2009, 75(1): 156-163.
[15] Bleeker F E, Molenaar R J, Leenstra S. Recent advances in the molecular understanding of glioblastoma [J]. J Neuroon- col, 2012, 108(1): 11-27.
[16] Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab [J]. Neuro Oncol, 2009, 11(5): 550-555.
[17] Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glio- blastoma [J]. Neurology, 2009, 73(15): 1200-1206.
[18] Chamberlain M C. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas [J]. Cancer, 2010, 116(17): 3988-3999.

相似文献/References:

[1]闫 进 李 松 杨 辉.1H-MRS对卵泡刺激素免疫阳性垂体腺瘤的诊断和预后评估的价值[J].中国临床神经外科杂志,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
 YAN Jin,LI Song,YANG Hui..Value of 1H-MRS to diagnosis and assessment of prognoses in patients with non-functioning gonadotroph adenomas[J].,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
[2]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
 LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(10):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[3]孙文栋 甘 宁 刘思思 李春晖.胶质肉瘤1例[J].中国临床神经外科杂志,2015,(06):356.[doi:10.13798/j.issn.1009-153X.2015.06.012]
[4]祝 斐 颉 奎 饶 敏 黄 新 吴 明 金卫星 朱炯明.良性脑膜瘤术后复发的影响因素分析[J].中国临床神经外科杂志,2015,(02):90.[doi:10.13798/j.issn.1009-153X.2015.02.008]
 ZHU Fei,XIE Kui,RAO Min,et al.Analysis of factors related to postoperative recurrence of benign meningiomas[J].,2015,(10):90.[doi:10.13798/j.issn.1009-153X.2015.02.008]
[5]邓友寿.经蝶入路切除垂体腺瘤的疗效及复发影响因素分析[J].中国临床神经外科杂志,2016,(09):533.[doi:10.13798/j.issn.1009-153X.2016.09.008]
 DENG You-shou..An analysis of curative effect of transsphenoidal surgery on pituitary adenomas and factors related to relapse in the patients with pituitary adenomas[J].,2016,(10):533.[doi:10.13798/j.issn.1009-153X.2016.09.008]
[6]李正伟、徐成仕、陈新军、李志强、江普查、陈劲草.夹闭术治疗栓塞后复发的颅内动脉瘤的疗效分析[J].中国临床神经外科杂志,2017,(08):542.[doi:10.13798/j.issn.1009-153X.2017.08.006]
 LI Zheng-wei,XU Cheng-shi,CHEN Xin-jun,et al.Microsurgical management of recurrent intracranial aneurysms after embolization[J].,2017,(10):542.[doi:10.13798/j.issn.1009-153X.2017.08.006]
[7]孙文华 樊翊凌 丁圣豪 赵 兵 潘耀华 万杰清.亚急性、慢性椎-基底动脉闭塞的血管内再通治疗分析[J].中国临床神经外科杂志,2017,(08):545.[doi:10.13798/j.issn.1009-153X.2017.08.007]
 SUN Wen-hua,FAN Yi-ling,DING Sheng-hao,et al.Curative effects of endovascular recanalization on subacute and chronic vertebrobasilar artery occlusion[J].,2017,(10):545.[doi:10.13798/j.issn.1009-153X.2017.08.007]
[8]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
 GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(10):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[9]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
 WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(10):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[10]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
 ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(10):69.
[11]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
 XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(10):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]

更新日期/Last Update: 2015-10-30